glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Long-term of in obesity and cardiovascular disease in the SELECT Effects of Once-Weekly Semaglutide on

"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Published in Nature Medicine, Accessed on November 13, 2023 at National Center for Biotechnology Information (NCBI)

Some Ozempic patients who experienced these complications had to be hospitalized to treat these conditions

This proportional muscle loss is consistent with weight loss from any cause, including dietary restriction or bariatric surgery, but the rapidity of weight loss with these medications may make this effect more clinically apparent

In addition to patient history, doctors assess factors such as: The severity of obesity and related health risks The patients ability to adhere to medication schedules and lifestyle changes Potential side effects and contraindications of each medication Specific mechanisms of action of the drugs, such as appetite suppression or metabolic enhancement The patients preferences and comfort with administration methods (e.g., injections vs

An arginine substitution at position 34 removes an immunogenic risk present in native GLP-1

The trial is sponsored by Bayer, the company that makes finerenone